ATAD1 and malaria: Antibody-mediated protection could be achieved against the P. yoelii mouse model of blood-stage malaria infection by using a priming immunization with an adenovirus vector followed by a booster immunization with the poxvirus vector MVA, and this approach targeting the blood-stage malaria antigens merozoite surface protein 1 (MSP1) and apical membrane antigen 1 (AMA1) has since entered Phase I/IIa clinical trials [27], showing this regime to be safe and similarly immunogenic in humans [28].